Literature DB >> 30260759

The 46th David A. Karnofsky Memorial Award Lecture: Oligometastasis-From Conception to Treatment.

Ralph R Weichselbaum1.   

Abstract

Metastasis from most adult solid tumors generally has been considered to be widespread and incurable. Here, I present clinical and molecular data to support the hypothesis that some metastases are limited in number and pace and are curable with ablative therapies. I advance the hypothesis that immunotherapy combined with radiotherapy may be a general strategy to increase the number of patients with metastatic cancer amenable to cure. I further suggest that, in the context of ablative radiotherapy, the potential synergies between immunotherapy and radiotherapy are principally within the local tumor microenvironment and require treatment of all or most sites of metastatic disease. Improvements in the molecular staging of metastasis, immunotherapy strategies, and radiotherapy delivery are likely to improve outcomes for patients with metastatic cancer.

Entities:  

Year:  2018        PMID: 30260759     DOI: 10.1200/JCO.18.00847

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  12 in total

1.  Metastasectomy for visceral and skeletal oligorecurrent prostate cancer.

Authors:  Antonino Battaglia; Gaëtan Devos; Karel Decaestecker; Manuel Witters; Lisa Moris; Thomas Van den Broeck; Charlien Berghen; Wouter Everaerts; Maarten Albersen; Arman Tsaturyan; Gert De Meerleer; Hein Van Poppel; Karolien Goffin; Piet Ost; Lorenzo Tosco; Steven Joniau
Journal:  World J Urol       Date:  2019-03-12       Impact factor: 4.226

2.  Local consolidative therapy for oligometastatic patients with stage IV non-small cell lung cancer may improve survival, but unanswered questions remain.

Authors:  Jose M Pacheco; Drew Moghanaki
Journal:  Transl Lung Cancer Res       Date:  2019-12

3.  Signals from SABR-COMET time to move on to phase III studies.

Authors:  Michael T Milano; Amit K Chowdhry; Joseph K Salama; Steven J Chmura
Journal:  Ann Transl Med       Date:  2019-12

4.  Metastasectomy of oligometastatic urothelial cancer: a single-center experience.

Authors:  Tim Muilwijk; Murat Akand; Frank Van der Aa; Herlinde Dumez; Gert De Meerleer; Dirk Van Raemdonck; Paul De Leyn; Hendrik Van Poppel; Maarten Albersen; Steven Joniau
Journal:  Transl Androl Urol       Date:  2020-06

5.  Tumor-reprogrammed resident T cells resist radiation to control tumors.

Authors:  Ainhoa Arina; Michael Beckett; Christian Fernandez; Wenxin Zheng; Sean Pitroda; Steven J Chmura; Jason J Luke; Martin Forde; Yuzhu Hou; Byron Burnette; Helena Mauceri; Israel Lowy; Tasha Sims; Nikolai Khodarev; Yang-Xin Fu; Ralph R Weichselbaum
Journal:  Nat Commun       Date:  2019-09-02       Impact factor: 14.919

6.  Long-term survival in patients with metastatic head and neck squamous cell carcinoma treated with metastasis-directed therapy.

Authors:  Thomas H Beckham; Jonathan E Leeman; Peng Xie; Xiaolin Li; Debra A Goldman; Zhigang Zhang; Eric Sherman; Sean McBride; Nadeem Riaz; Nancy Lee; C Jillian Tsai
Journal:  Br J Cancer       Date:  2019-10-25       Impact factor: 7.640

7.  Efficacy of Local Therapy for Oligometastatic Hepatocellular Carcinoma: A Propensity Score Matched Analysis.

Authors:  Kangpyo Kim; Tae Hyung Kim; Tae Hyun Kim; Jinsil Seong
Journal:  J Hepatocell Carcinoma       Date:  2021-02-11

Review 8.  Circulating Tumor DNA Biomarkers for Early Detection of Oligometastasis.

Authors:  David M Routman; Bhishamjit S Chera; Gaorav P Gupta
Journal:  Cancer J       Date:  2020 Mar/Apr       Impact factor: 2.074

9.  Proposal for a definition of "Oligometastatic disease in pancreatic cancer".

Authors:  Alexander I Damanakis; Luisa Ostertag; Dirk Waldschmidt; Fabian Kütting; Alexander Quaas; Patrick Plum; Christiane J Bruns; Florian Gebauer; Felix Popp
Journal:  BMC Cancer       Date:  2019-12-30       Impact factor: 4.430

10.  Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.

Authors:  Ryan Phillips; William Yue Shi; Matthew Deek; Noura Radwan; Su Jin Lim; Emmanuel S Antonarakis; Steven P Rowe; Ashley E Ross; Michael A Gorin; Curtiland Deville; Stephen C Greco; Hailun Wang; Samuel R Denmeade; Channing J Paller; Shirl Dipasquale; Theodore L DeWeese; Daniel Y Song; Hao Wang; Michael A Carducci; Kenneth J Pienta; Martin G Pomper; Adam P Dicker; Mario A Eisenberger; Ash A Alizadeh; Maximilian Diehn; Phuoc T Tran
Journal:  JAMA Oncol       Date:  2020-05-01       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.